Strategic use of dual regimens of boosted protease inhibitors plus maraviroc in poorly adherent subjects in view of long-acting drugs: A retrospective study

In view of the forthcoming long-acting antiretrovirals, measures should be taken to prevent the selection of HIV drug resistance mutations. All subjects who had been switched to boosted protease inhibitors plus maraviroc (bPIs/MVC) with baseline HIV-1 RNA >50 copies/mL between June, 2014, and Apr...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Medicine (Baltimore)
Egile Nagusiak: Capetti, Amedeo Ferdinando, Micale, Mariangela, Carenzi, Laura, Niero, Fosca, Landonio, Simona, Vimercati, Stefania, Dedivitiis, Gianfranco, Rizzardini, Giuliano
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Wolters Kluwer Health 2017
Gaiak:
4850
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5319489/
https://ncbi.nlm.nih.gov/pubmed/28207500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000005728
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak